US Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) Forecasts 2022-2032
US Preimplantation Genetic Diagnosis Market is valued at approximately USD 23.62 million in 2023 and is anticipated to grow with a healthy growth rate of more than 11.40% over the forecast period 2024-2032. Preimplantation Genetic Diagnosis (PGD) is a sophisticated reproductive technology used with In Vitro Fertilization (IVF) to screen embryos for genetic conditions before implantation. This technique enhances the likelihood of a healthy baby for couples at risk of passing on genetic conditions. IVF involves hormone stimulation of the ovaries, egg retrieval, and fertilization in a lab. Embryos are cultured to the blastocyst stage, where cells are biopsied and assessed for genetic defects. Only healthy embryos are selected for uterine transfer, reducing the transmission of genetic disorders and improving IVF success rates. PGD raises ethical concerns about embryo selection and genetic confidentiality but is beneficial for couples with a family history of genetic issues, multiple miscarriages, or infertility due to genetic abnormalities. The US Preimplantation Genetic Diagnosis Market is growing due to advancements in genetic technologies, increasing awareness of genetic disorders, and the trend of delayed parenthood. Rising infertility rates and expanding applications of PGD for non-medical purposes further drive market growth.
The US Preimplantation Genetic Diagnosis (PGD) market is driven by the increasing prevalence of genetic disorders, prompting more couples to opt for PGD to avoid passing on hereditary conditions to their children. PGD's ability to provide genetic information about embryos before implantation is a crucial factor driving its adoption among couples undergoing fertility treatments, as it enhances the chances of a successful pregnancy. The rises trend of delayed parenthood, coupled with increasing awareness about fertility preservation, is expected to drive the demand for PGD services in the US market. However, the market faces certain restraints. The high cost associated with PGD procedures is a barrier for many couples seeking these services. Ethical and legal concerns surrounding the use of PGD, particularly regarding embryo selection for non-medical reasons, pose challenges to market growth. Furthermore, the lack of insurance coverage for PGD procedures in some cases limits its accessibility to a broader population.
Major market players included in this report are:
Illumina, Inc.
Thermo Fisher Scientific Inc
Agilent Technologies, Inc.
PerkinElmer, Inc.
CooperSurgical, Inc.
Natera, Inc
Invitae Corporation
F. Hoffmann-La Roche Ltd
Good Start Genetics, Inc
Laboratory Corporation of America Holdings
The detailed segments and sub-segments of the market are explained below:
By Test Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single Gene Disorders
HLA Typing
Gender selection
Others
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
The US Preimplantation Genetic Diagnosis (PGD) market is driven by the increasing prevalence of genetic disorders, prompting more couples to opt for PGD to avoid passing on hereditary conditions to their children. PGD's ability to provide genetic information about embryos before implantation is a crucial factor driving its adoption among couples undergoing fertility treatments, as it enhances the chances of a successful pregnancy. The rises trend of delayed parenthood, coupled with increasing awareness about fertility preservation, is expected to drive the demand for PGD services in the US market. However, the market faces certain restraints. The high cost associated with PGD procedures is a barrier for many couples seeking these services. Ethical and legal concerns surrounding the use of PGD, particularly regarding embryo selection for non-medical reasons, pose challenges to market growth. Furthermore, the lack of insurance coverage for PGD procedures in some cases limits its accessibility to a broader population.
Major market players included in this report are:
Illumina, Inc.
Thermo Fisher Scientific Inc
Agilent Technologies, Inc.
PerkinElmer, Inc.
CooperSurgical, Inc.
Natera, Inc
Invitae Corporation
F. Hoffmann-La Roche Ltd
Good Start Genetics, Inc
Laboratory Corporation of America Holdings
The detailed segments and sub-segments of the market are explained below:
By Test Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single Gene Disorders
HLA Typing
Gender selection
Others
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
CHAPTER 1. US PREIMPLANTATION GENETIC DIAGNOSIS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
CHAPTER 2. EXECUTIVE SUMMARY
2.1. US Preimplantation Genetic Diagnosis Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Test Type
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
CHAPTER 3. US PREIMPLANTATION GENETIC DIAGNOSIS MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
CHAPTER 4. US PREIMPLANTATION GENETIC DIAGNOSIS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. US PREIMPLANTATION GENETIC DIAGNOSIS MARKET SIZE & FORECASTS BY TEST TYPE 2022-2032
5.1. Chromosomal Abnormalities
5.2. Aneuploidy
5.3. X-linked diseases
5.4. Single Gene Disorders
5.5. HLA Typing
5.6. Gender selection
5.7. Others
CHAPTER 6. COMPETITIVE INTELLIGENCE
6.1. Key Company SWOT Analysis
6.1.1. Company
6.1.2. Company
6.1.3. Company
6.2. Top Market Strategies
6.3. Company Profiles
6.3.1. Illumina, Inc.
6.3.1.1. Key Information
6.3.1.2. Overview
6.3.1.3. Financial (Subject to Data Availability)
6.3.1.4. Product Summary
6.3.1.5. Market Strategies
6.3.2. Thermo Fisher Scientific Inc
6.3.3. Agilent Technologies, Inc.
6.3.4. PerkinElmer, Inc.
6.3.5. CooperSurgical, Inc.
6.3.6. Natera, Inc
6.3.7. Invitae Corporation
6.3.8. F. Hoffmann-La Roche Ltd
6.3.9. Good Start Genetics, Inc
6.3.10. Laboratory Corporation of America Holdings
CHAPTER 7. RESEARCH PROCESS
7.1. Research Process
7.1.1. Data Mining
7.1.2. Analysis
7.1.3. Market Estimation
7.1.4. Validation
7.1.5. Publishing
7.2. Research Attributes
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
CHAPTER 2. EXECUTIVE SUMMARY
2.1. US Preimplantation Genetic Diagnosis Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Test Type
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
CHAPTER 3. US PREIMPLANTATION GENETIC DIAGNOSIS MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
CHAPTER 4. US PREIMPLANTATION GENETIC DIAGNOSIS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. US PREIMPLANTATION GENETIC DIAGNOSIS MARKET SIZE & FORECASTS BY TEST TYPE 2022-2032
5.1. Chromosomal Abnormalities
5.2. Aneuploidy
5.3. X-linked diseases
5.4. Single Gene Disorders
5.5. HLA Typing
5.6. Gender selection
5.7. Others
CHAPTER 6. COMPETITIVE INTELLIGENCE
6.1. Key Company SWOT Analysis
6.1.1. Company
6.1.2. Company
6.1.3. Company
6.2. Top Market Strategies
6.3. Company Profiles
6.3.1. Illumina, Inc.
6.3.1.1. Key Information
6.3.1.2. Overview
6.3.1.3. Financial (Subject to Data Availability)
6.3.1.4. Product Summary
6.3.1.5. Market Strategies
6.3.2. Thermo Fisher Scientific Inc
6.3.3. Agilent Technologies, Inc.
6.3.4. PerkinElmer, Inc.
6.3.5. CooperSurgical, Inc.
6.3.6. Natera, Inc
6.3.7. Invitae Corporation
6.3.8. F. Hoffmann-La Roche Ltd
6.3.9. Good Start Genetics, Inc
6.3.10. Laboratory Corporation of America Holdings
CHAPTER 7. RESEARCH PROCESS
7.1. Research Process
7.1.1. Data Mining
7.1.2. Analysis
7.1.3. Market Estimation
7.1.4. Validation
7.1.5. Publishing
7.2. Research Attributes
LIST OF TABLES
TABLE 1. US Preimplantation Genetic Diagnosis market, report scope
TABLE 2. US Preimplantation Genetic Diagnosis market estimates & forecasts by Test Type 2022-2032 (USD Million)
TABLE 3. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 4. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 5. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 6. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 7. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 8. U.S. Preimplantation Genetic Diagnosis market estimates & forecasts, 2022-2032 (USD Million)
TABLE 9. U.S. Preimplantation Genetic Diagnosis market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 10. U.S. Preimplantation Genetic Diagnosis market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 11. List of secondary sources, used in the study of US Preimplantation Genetic Diagnosis Market.
TABLE 12. List of primary sources, used in the study of US Preimplantation Genetic Diagnosis Market.
TABLE 13. Years considered for the study.
TABLE 14. Exchange rates considered.
TABLE 1. US Preimplantation Genetic Diagnosis market, report scope
TABLE 2. US Preimplantation Genetic Diagnosis market estimates & forecasts by Test Type 2022-2032 (USD Million)
TABLE 3. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 4. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 5. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 6. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 7. US Preimplantation Genetic Diagnosis market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 8. U.S. Preimplantation Genetic Diagnosis market estimates & forecasts, 2022-2032 (USD Million)
TABLE 9. U.S. Preimplantation Genetic Diagnosis market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 10. U.S. Preimplantation Genetic Diagnosis market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 11. List of secondary sources, used in the study of US Preimplantation Genetic Diagnosis Market.
TABLE 12. List of primary sources, used in the study of US Preimplantation Genetic Diagnosis Market.
TABLE 13. Years considered for the study.
TABLE 14. Exchange rates considered.
LIST OF FIGURES
FIG 1. US Preimplantation Genetic Diagnosis market, research methodology
FIG 2. US Preimplantation Genetic Diagnosis market, market estimation techniques
FIG 3. US market size estimates & forecast methods.
FIG 4. US Preimplantation Genetic Diagnosis market, key trends 2023
FIG 5. US Preimplantation Genetic Diagnosis market, growth prospects 2022-2032
FIG 6. US Preimplantation Genetic Diagnosis market, porters 5 force model
FIG 7. US Preimplantation Genetic Diagnosis market, pestel analysis
FIG 8. US Preimplantation Genetic Diagnosis market, value chain analysis
FIG 9. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 10. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 11. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 12. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 13. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 14. US Preimplantation Genetic Diagnosis market, company market share analysis (2023)
FIG 1. US Preimplantation Genetic Diagnosis market, research methodology
FIG 2. US Preimplantation Genetic Diagnosis market, market estimation techniques
FIG 3. US market size estimates & forecast methods.
FIG 4. US Preimplantation Genetic Diagnosis market, key trends 2023
FIG 5. US Preimplantation Genetic Diagnosis market, growth prospects 2022-2032
FIG 6. US Preimplantation Genetic Diagnosis market, porters 5 force model
FIG 7. US Preimplantation Genetic Diagnosis market, pestel analysis
FIG 8. US Preimplantation Genetic Diagnosis market, value chain analysis
FIG 9. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 10. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 11. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 12. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 13. US Preimplantation Genetic Diagnosis market by segment, 2022 & 2032 (USD Million)
FIG 14. US Preimplantation Genetic Diagnosis market, company market share analysis (2023)
